Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NMTC 
Neuroone Medical Technologies Corp (NMTC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: NMTC (1-star) is a SELL. SELL since 3 days. Profits (9.59%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1.45
1 Year Target Price $1.45
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -41.46% | Avg. Invested days 30 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 41.35M USD | Price to earnings Ratio - | 1Y Target Price 1.45 |
Price to earnings Ratio - | 1Y Target Price 1.45 | ||
Volume (30-day avg) 1 | Beta 0.68 | 52 Weeks Range 0.40 - 1.39 | Updated Date 08/15/2025 |
52 Weeks Range 0.40 - 1.39 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.23 |
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.05 | Actual -0.03 |
Profitability
Profit Margin -114.67% | Operating Margin (TTM) -193.29% |
Management Effectiveness
Return on Assets (TTM) -83.48% | Return on Equity (TTM) -265.18% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 40339965 | Price to Sales(TTM) 7.18 |
Enterprise Value 40339965 | Price to Sales(TTM) 7.18 | ||
Enterprise Value to Revenue 7 | Enterprise Value to EBITDA -2.1 | Shares Outstanding 49817800 | Shares Floating 46944342 |
Shares Outstanding 49817800 | Shares Floating 46944342 | ||
Percent Insiders 11.76 | Percent Institutions 26.17 |
Upturn AI SWOT
Neuroone Medical Technologies Corp
Company Overview
History and Background
Neuroone Medical Technologies Corp. is a medical technology company focused on improving surgical care through advanced solutions. Details on founding year and historical milestones unavailable. Focus is on developing and commercializing innovative medical devices and technologies.
Core Business Areas
- Cortical Interface Technology: Development of thin-film electrode technology used for electrophysiological recording, stimulation, and drug delivery, applicable in neurosurgery and neurology.
- Bioengineered Neural Probes: Creating innovative neural probes for advanced diagnostic and therapeutic applications within the central nervous system.
Leadership and Structure
Information on specific leadership team and organizational structure is not readily available.
Top Products and Market Share
Key Offerings
- evo Cortical Electrode: Thin-film electrode designed for intraoperative neuromonitoring and electrocorticography. Market share data unavailable. Competitors: Integra LifeSciences (IART), Medtronic (MDT).
- Neuro Monitoring Accessories: Accessories and instruments for neurosurgical application. Market share data unavailable. Competitors: Integra LifeSciences (IART), Medtronic (MDT).
Market Dynamics
Industry Overview
The neurotechnology market is growing, driven by advancements in neurosurgery, neurology, and neurodiagnostics. Demand is fueled by an aging population and increasing prevalence of neurological disorders.
Positioning
Neuroone aims to be a key player in the neurotechnology space by offering innovative cortical interface technologies, but faces competition from established players and smaller, specialized firms.
Total Addressable Market (TAM)
The global neurotechnology market is estimated in the billions. NeuroOne is positioned to capture a segment of this TAM through their cortical electrode technology, however specific TAM metrics are unavailable due to the varied applications.
Upturn SWOT Analysis
Strengths
- Proprietary thin-film electrode technology
- Potential for improved surgical outcomes
- Focus on minimally invasive neurosurgery
Weaknesses
- Limited commercialization history
- High reliance on regulatory approvals
- Limited financial resources (small cap)
- Lack of clear public information
Opportunities
- Expanding applications of cortical interface technology
- Partnerships with larger medical device companies
- Increasing demand for minimally invasive neurosurgical procedures
Threats
- Competition from established medical device companies
- Regulatory hurdles and delays
- Technological obsolescence
- Small cap risk
Competitors and Market Share
Key Competitors
- IART
- MDT
- STM
- ABMD
Competitive Landscape
Neuroone faces significant competition from larger, more established companies with greater resources. Its competitive advantage lies in its thin-film electrode technology and focus on minimally invasive neurosurgery.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is not readily available.
Future Projections: Future growth projections require analyst estimates, and that information is not readily available.
Recent Initiatives: Initiatives include product development and seeking regulatory approvals.
Summary
Neuroone is a small company in the neurotechnology sector with a unique technology offering. The company faces intense competition and relies on the successful commercialization of its evo Cortical Electrode. Financial details are scarce, adding to the uncertainty. Success hinges on innovation, regulatory approval, and strategic partnerships. Further due diligence is needed.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neuroone Medical Technologies Corp
Exchange NASDAQ | Headquaters Eden Prairie, MN, United States | ||
IPO Launch date 2017-09-18 | President, CEO & Director Mr. David A. Rosa M.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 17 | Website https://nmtc1.com |
Full time employees 17 | Website https://nmtc1.com | ||
NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States. The company also provides solutions for spinal cord stimulation, radio frequency and brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-related neurological disorders. The company also focuses on applications of its technology associated with artificial intelligence. It has partnership with RBC Medical Innovations to develop a radio frequency ablation generator. NeuroOne Medical Technologies Corporation is based in Eden Prairie, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.